Trends associated with implementing and lifting a pregabalin step therapy policy

American Journal of Pharmacy Benefits

Volumn 8, Issue 2, 2016, Pages

  Null, Kyle D ^a   Moll, Keran ^a   Sadosky, Alesia ^b   Pasquale, Margaret K ^a   Cappelleri, Joseph C ^b   Parsons, Bruce ^b  

^a Formerly of Comprehensive Health Insights Inc   (United States)

^b PFIZER INC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTICONVULSIVE AGENT; GABAPENTIN; NARCOTIC ANALGESIC AGENT; OPIATE; PREGABALIN; SEROTONIN UPTAKE INHIBITOR; TRIPLE REUPTAKE INHIBITOR;

ARTICLE; COST BENEFIT ANALYSIS; DIABETIC NEUROPATHY; FIBROMYALGIA; HEALTH CARE COST; HEALTH CARE PERSONNEL; HUMAN; MEDICARE; NEUROPATHIC PAIN; POSTHERPETIC NEURALGIA; RANDOMIZED CONTROLLED TRIAL (TOPIC); REGRESSION ANALYSIS; RETROSPECTIVE STUDY; SPINAL CORD INJURY;

EID: 84991738689     PISSN: 19454481     EISSN: 21642494     Source Type: Journal    
DOI: None     Document Type: Article

References (19)

1. Lyrica [package insert]. New York, NY: Pfizer, Inc; 2013
2. Bril V, England J, Franklin G, et al; American Academy of Neurology; American Association of Neuromuscular and Electrodiagnostic Medicine; American Academy of Physical Medicine and Rehabilitation. Evidence-based guideline: treatment of painful diabetic neuropathy: report of the American Academy of Neurology, the American Association of Neuromuscular and Electrodiagnostic Medicine, and the American Academy of Physical Medicine and Rehabilitation. Neurology. 2011;76(20):1758-1765
3. Carville SF, Arendt-Nielsen L, Bliddal H, et al; EULAR. EULAR evidence-based recommendations for the management of fibromyalgia syndrome. Ann Rheum Dis. 2008;67(4):536-541
4. Häuser W, Walitt B, Fitzcharles MA, Sommer C. Review of pharmacological therapies in fibromyalgia syndrome. Arthritis Res Ther. 2014;16(1):201. doi: 10.1186/ar4441.
5. Gore M, Tai KS, Chandran A, Zlateva G, Leslie D. Clinical comorbidities, treatment patterns, and healthcare costs among patients with fibromyalgia newly prescribed pregabalin or duloxetine in usual care. J Med Econ. 2012;15(1):19-31. doi: 10.3111/13696998.2011.629262
6. Gore M, Tai KS, Zlateva G, Bala Chandran A, Leslie D. Clinical characteristics, pharmacotherapy, and healthcare resource use among patients with diabetic neuropathy newly prescribed pregabalin or gabapentin. Pain Pract. 2011;11(6):528-539
7. Berger A, Dukes E, Martin S, Edelsberg J, Oster G. Characteristics and healthcare costs of patients with fibromyalgia syndrome. Int J Clin Pract. 2007;61(9):1498-1508
8. Udall M, Harnett J, Mardekian J. Costs of pregabalin or gabapentin for painful diabetic peripheral neuropathy. J Med Econ. 2012;15(2):361-370
9. Suehs BT, Louder A, Udall M, Cappelleri JC, Joshi AV, Patel NC. Impact of a pregabalin step therapy policy among Medicare Advantage beneficiaries. Pain Pract. 2014;14(5):419-426. doi: 10.1111/papr.12073
10. Johnston SS, Udall M, Alvir J, et al. Association between pregabalin access restrictions and pain-related health care utilization and expenditures in medicare supplemental health plans. Poster presented at: Academy of Managed Care Pharmacy’s 2012 Educational Conference; October 3-5, 2012; Cincinnati, OH
11. Margolis JM, Johnston SS, Chu BC, et al. Effects of a Medicaid prior authorization policy for pregabalin. Am J Manag Care. 2009;15(9):e95-e102
12. Margolis JM, Cao Z, Onukwugha E, et al. Healthcare utilization and cost effects of prior authorization for pregabalin in commercial health plans. Am J Manag Care. 2010;16(6):447-456
13. Udall M, Louder A, Suehs BT, Cappelleri JC, Joshi AV, Patel NC. Impact of a step-therapy protocol for pregabalin on healthcare utilization and expenditures in a commercial population. J Med Econ. 2013;16(6):784-792. doi:10.3111/13696998.2013.793692
14. Wagner AK, Soumerai SB, Zhang F, Ross-Degnan D. Segmented regression analysis of interrupted time series studies in medication use research. J Clin Pharm Ther. 2002;27(4):299-309
15. Shadish WR, Cook TD, Campbell DT. Experimental and Quasi-Experimental Designs for Generalized Causal Inference. Boston, MA: Houghton Mifflin Company; 2002
16. Jandoc R, Burden AM, Mamdani M, Lévesque LE, Cadarette SM. Interrupted times series analysis in drug utilization research is increasing: systematic review and recommendations. J Clin Epidemiol. 2015;68(8):950-956. doi: 10.1016/j.jclinepi.2014.12.018
17. Gujarati D, Porter D. Basic Econometrics. 5th ed. New York, NY: McGraw Hill / Irwin; 2008
18. Humana. Lyrica (pregabalin) Pharmacy Coverage Policy. 2014. http://apps.humana.com/tad/tad_new/Search.aspx?searchtype=beginswith&docbegin=L&poli cyType=pharmacy
19. Cox ER, Henderson R, Motheral BR. Health plan member experience with point-of-service prescription step therapy. J Manag Care Pharm. 2004;10(4):291-298